Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axonics, Inc. stock logo
AXNX
Axonics
$70.98
$70.61
$67.90
$71.05
$3.63B0.82437,262 shsN/A
Penumbra, Inc. stock logo
PEN
Penumbra
$253.19
-1.6%
$246.16
$184.19
$310.00
$10.04B0.4517,820 shs332,526 shs
Solventum Corporation stock logo
SOLV
Solventum
$73.24
-1.5%
$74.08
$57.86
$85.92
$12.90B0.52708,444 shs4.86 million shs
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€22.23
-0.6%
€24.50
€17.12
€28.00
€6.73B0.55341,950 shs288,800 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axonics, Inc. stock logo
AXNX
Axonics
0.00%0.00%0.00%0.00%+3.24%
Penumbra, Inc. stock logo
PEN
Penumbra
+3.27%+7.34%+7.89%-6.62%+37.79%
Solventum Corporation stock logo
SOLV
Solventum
+3.19%+2.34%+0.31%+1.89%+27.64%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
+2.76%-7.30%-12.52%-3.54%+7.97%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Axonics, Inc. stock logo
AXNX
Axonics
1.5104 of 5 stars
0.00.00.04.10.61.71.9
Penumbra, Inc. stock logo
PEN
Penumbra
4.8258 of 5 stars
3.55.00.03.73.42.51.9
Solventum Corporation stock logo
SOLV
Solventum
2.6999 of 5 stars
3.13.00.00.03.80.01.3
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
1.9338 of 5 stars
0.04.00.80.02.60.01.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Axonics, Inc. stock logo
AXNX
Axonics
2.00
HoldN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
2.94
Moderate Buy$300.4718.67% Upside
Solventum Corporation stock logo
SOLV
Solventum
2.27
Hold$85.7517.09% Upside
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
2.83
Moderate BuyN/AN/A

Current Analyst Ratings Breakdown

Latest AXNX, SOLV, PEN, and STVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/8/2025
Solventum Corporation stock logo
SOLV
Solventum
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$75.00 ➝ $79.00
8/8/2025
Solventum Corporation stock logo
SOLV
Solventum
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$87.00 ➝ $94.00
7/31/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$260.00 ➝ $266.00
7/30/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$300.00 ➝ $310.00
7/30/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$330.00 ➝ $325.00
7/30/2025
Penumbra, Inc. stock logo
PEN
Penumbra
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$330.00 ➝ $335.00
7/30/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$315.00 ➝ $290.00
7/30/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$283.00 ➝ $285.00
7/30/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$340.00 ➝ $350.00
7/18/2025
Penumbra, Inc. stock logo
PEN
Penumbra
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/15/2025
Solventum Corporation stock logo
SOLV
Solventum
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$80.00 ➝ $103.00
(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Axonics, Inc. stock logo
AXNX
Axonics
$366.38M9.90$0.13 per share561.96$12.59 per share5.64
Penumbra, Inc. stock logo
PEN
Penumbra
$1.28B7.71$2.84 per share89.16$33.18 per share7.63
Solventum Corporation stock logo
SOLV
Solventum
$8.25B1.54$9.79 per share7.48$21.02 per share3.48
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€1.19B5.63€0.75 per share29.62€5.24 per share4.24
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Axonics, Inc. stock logo
AXNX
Axonics
-$6.09M-$0.12N/A80.66N/A-1.31%0.36%0.31%N/A
Penumbra, Inc. stock logo
PEN
Penumbra
$14.01M$3.7667.3450.542.3111.54%11.55%8.76%10/29/2025 (Estimated)
Solventum Corporation stock logo
SOLV
Solventum
$478M$2.1633.9113.341.804.52%29.93%6.65%N/A
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€127.45M€0.5441.1738.332.1111.73%10.34%6.21%N/A

Latest AXNX, SOLV, PEN, and STVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Solventum Corporation stock logo
SOLV
Solventum
$1.45$1.69+$0.24$0.51$2.12 billion$2.16 billion
7/29/2025Q2 2025
Penumbra, Inc. stock logo
PEN
Penumbra
$0.81$0.86+$0.05$1.15$327.37 million$339.46 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Axonics, Inc. stock logo
AXNX
Axonics
N/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A
Solventum Corporation stock logo
SOLV
Solventum
N/AN/AN/AN/AN/A
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/AN/AN/AN/A1 Years
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Axonics, Inc. stock logo
AXNX
Axonics
N/A
8.16
6.40
Penumbra, Inc. stock logo
PEN
Penumbra
0.02
6.75
4.04
Solventum Corporation stock logo
SOLV
Solventum
2.14
1.22
0.86
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.25
1.79
1.22

Institutional Ownership

CompanyInstitutional Ownership
Axonics, Inc. stock logo
AXNX
Axonics
99.48%
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%
Solventum Corporation stock logo
SOLV
Solventum
N/A
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/A

Insider Ownership

CompanyInsider Ownership
Axonics, Inc. stock logo
AXNX
Axonics
1.85%
Penumbra, Inc. stock logo
PEN
Penumbra
4.20%
Solventum Corporation stock logo
SOLV
Solventum
0.05%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Axonics, Inc. stock logo
AXNX
Axonics
61051.11 million50.16 millionOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
4,50039.00 million37.36 millionOptionable
Solventum Corporation stock logo
SOLV
Solventum
22,000173.39 million173.30 millionOptionable
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
5,521302.84 million300.72 millionOptionable

Recent News About These Companies

USNA vs. STVN: Which Stock Is the Better Value Option?
William Blair Cuts Earnings Estimates for Stevanato Group

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Axonics stock logo

Axonics NASDAQ:AXNX

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Penumbra stock logo

Penumbra NYSE:PEN

$253.19 -4.19 (-1.63%)
Closing price 03:59 PM Eastern
Extended Trading
$252.84 -0.34 (-0.14%)
As of 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Solventum stock logo

Solventum NYSE:SOLV

$73.24 -1.14 (-1.54%)
Closing price 03:59 PM Eastern
Extended Trading
$71.98 -1.25 (-1.71%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.

Stevanato Group stock logo

Stevanato Group NYSE:STVN

€22.23 -0.13 (-0.58%)
As of 03:58 PM Eastern

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.